

## REMARKS

The undersigned thanks the Examiner for his courtesy in a brief phone call of June 1, 2006, in which the undersigned introduced himself, informed the Examiner that he was assuming responsibility for prosecution of this and all other pending applications assigned to Epitome Biosystems, Inc., and received helpful clarification on the requirement for election of species issued in this application. Applicants enclose with this response a document to change the power of attorney and correspondence address for this application, and respectfully request that the Patent Office identify future correspondence for this application with the new Attorney Docket Number EPT-001C1.

Claims 36-125 have been cancelled without prejudice to their subsequent reintroduction into a related application, and new claims 126-132 have been added. Support for new claims 126-132 can be found throughout the application as filed, for example, in the original claims that the new claims depend from. Applicants believe that these amendments introduce no new matter. Claims 1-35 and 126-132 are currently pending in this application.

The Patent Office has required Applicants to elect from each of four groups one allegedly patentably distinct species to which the claims must be restricted:


- Species A, claims 2, 3, 23, 24, 27, 29, and 30, drawn to forms of post-translational modification and the location of the post-translational modification. The Office has required election of one form of post-translational modification, such as phosphorylation, and one location of post-translational modification.
- Species B, claims 9-11, drawn to types of capture agents. The Office has required election of one type of capture reagent.
- Species C, claims 14 and 15, drawn to types of treatment. The Office has required election of either claim 14 or 15.
- Species D, claims 23-90, drawn to types of secondary capture agents. Applicants believe that 23-90 is a typographical error, that should correctly read 23-30. The Office has required, election of one type of secondary capture reagent.

Applicants hereby elect, without traverse, the following. In Species A, Applicants elect phosphorylation as the post-translational modification, and tyrosine as the location of post-translational modification. In Species B, Applicants elect full-length antibody as the type of capture reagent. In Species C, Applicants elect the perceived species of claim 14. In Species D, Applicants elect fluorescent labels as the type of secondary capture agent. Claims 1-10, 12-25, 31-36, and 126-132 read on the elected combination of features.

Applicants understand that the Office perceives claims 1, 4-8, 12, 13, 16-22, and 31-36 as generic, and that upon allowance of a generic claim, Applicants are entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of the allowed generic claim. Applicants understand that the claims will be restricted to the elected species if no generic claim is finally held to be allowable, and reserve the right to pursue claims readable on any of the non-elected species in one or more related applications if the species election requirements are maintained.

Applicants respectfully request that the application now proceed promptly to examination. The Examiner is invited to contact the undersigned with any questions about this paper. Early favorable action is respectfully solicited.

Respectfully submitted,



Edmund R. Pitcher  
Attorney for Applicants  
Goodwin Procter LLP  
Exchange Place  
Boston, Massachusetts 02109  
Goodwin Customer No. 051414

Date: June 7, 2006  
Reg. No. 27,829

Tel. No.: (617) 570-1780  
Fax No.: (617) 523-1231